Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 34, Issue 11, 2015, Pages 2213-2223

  Rubio Terres C ^a   Cobo Reinoso, J ^b   Grau Cerrato, S ^c   Mensa Pueyo, J ^d   Salavert Lleti M ^e   Toledo, A ^f   Anguita, P ^f   Rubio Rodriguez D ^a   Watt, M ^g   Gani, R ^g  

^a Health Value   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c HOSPITAL DEL MAR   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f Astellas Pharma   (Spain)

^g Astellas Pharma EMEA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FIDAXOMICIN; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; CANCER PATIENT; CLOSTRIDIUM DIFFICILE INFECTION; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG DOSE INCREASE; DRUG MEGADOSE; HEALTH CARE COST; HEALTH STATUS; HUMAN; KIDNEY FAILURE; LENGTH OF STAY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RECURRENT DISEASE; SPAIN; TREATMENT DURATION; CHEMICALLY INDUCED; CLOSTRIDIUM INFECTIONS; COMPLICATION; COST BENEFIT ANALYSIS; DIARRHEA; DRUG EFFECTS; ECONOMICS; KIDNEY DISEASE; NEOPLASM; PEPTOCLOSTRIDIUM DIFFICILE; TREATMENT OUTCOME;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; COST-BENEFIT ANALYSIS; DIARRHEA; HUMANS; KIDNEY DISEASES; NEOPLASMS; QUALITY-ADJUSTED LIFE YEARS; SPAIN; TREATMENT OUTCOME; VANCOMYCIN;

EID: 84944313720     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-015-2472-0     Document Type: Article

References (47)

1. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, Gorbach S, Sears P, Shue YK; OPT- 80-003 Clinical Study Group (2011) Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 364:422–431
2. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, Sears P, Gorbach S; OPT-80-004 Clinical Study Group (2012) Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 12:281–289
3. Cornely OA, Miller MA, Fantin B, Mullane K, Kean Y, Gorbach S (2013) Resolution of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. J Clin Oncol 31:2493–2499
4. Mullane KM, Miller MA, Weiss K, Lentnek A, Golan Y, Sears PS, Shue YK, Louie TJ, Gorbach SL (2011) Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis 53:440–447
5. Mullane KM, Cornely OA, Crook DW, Golan Y, Louie TJ, Miller MA, Josephson MA, Gorbach SL (2013) Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials. Am J Nephrol 38:1–11
6. Monge D, Millán I, González-Escalada A, Asensio A (2013) The effect of Clostridium difficile infection on length of hospital stay. A cohort study. Enferm Infecc Microbiol Clin 31(10):660–664
7. Campbell R, Dean B, Nathanson B, Haidar T, Strauss M, Thomas S (2013) Length of stay and hospital costs among high-risk patients with hospital-origin Clostridium difficile-associated diarrhea. J Med Econ 16:440–448
8. Bujanda L, Cosme Á (2009) Diarrea asociada a Clostridium difficile. Gastroenterol Hepatol 32:48–56
9. Asensio A, Monge D (2012) Epidemiología de la infección por Clostridium difficile en España. Enferm Infecc Microbiol Clin 30:333–337
10. Davies KA, Longshaw CM, Davis GL, Bouza E, Barbut F, Barna Z, Delmée M, Fitzpatrick F, Ivanova K, Kuijper E, Macovei IS, Mentula S, Mastrantonio P, von Müller L, Oleastro M, Petinaki E, Pituch H, Norén T, Nováková E, Nyč O, Rupnik M, Schmid D, Wilcox MH (2014) Underdiagnosis of Clostridium difficile across Europe: the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID). Lancet Infect Dis 14:1208–1219
11. Monge D, Morosini M, Millán I, Pérez Canosa C, Manso M, Guzman MF, Asensio A (2011) Factores de riesgo de infección por Clostridium difficile en pacientes hospitalizados. Med Clin (Barc) 137:575–580
12. Asensio Á, Bouza E, Grau S, Rubio-Rodríguez D, Rubio-Terrés C (2013) Coste de la diarrea asociada a Clostridium difficile en España. Rev Esp Salud Publica 87:25–33
13. Johnson AP, Wilcox MH (2012) Fidaxomicin: a new option for the treatment of Clostridium difficile infection. J Antimicrob Chemother 67:2788–2792
14. Kelly CP (2012) Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect 18(Suppl 6):21–27. doi:10.1111/1469-0691.12046
15. Crawford T, Huesgen E, Danziger L (2012) Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection. Am J Health Syst Pharm 69:933–943
16. Real Decreto-ley 16/2012, de 20 de abril, de medidas urgentes para garantizar la sostenibilidad del Sistema Nacional de Salud y mejorar la calidad y seguridad de sus prestaciones. B.O.E. N° 98, 24 de abril de 2012: 31278.
17. Nathwani D, Cornely OA, Van Engen AK, Odufowora-Sita O, Retsa P, Odeyemi IA (2014) Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. J Antimicrob Chemother 69:2901–2912
18. fidaxomicin (Dificlir®) 200 mg film-coated tablet. All Wales Medicines Strategy Group, 1 June 2012
19. Scottish Medicines Consortium. fidaxomicin 200mg film-coated tablets (Dificlir®). SMC No. (791/12). Available online at: http://www.scottishmedicines.org.uk/files/advice/fidaxomicin_Dificlir_FINAL_June_2012_for_website.pdf. Accessed 23 Sep 2014
20. Lamotte M, Vellopoulou K, Richir K, Smets J, Grabe K, Coppens K (2013) The cost–utility of fidaxomicin as compared to current standard treatment in the management of Clostridium difficile infections in Belgium. Value Health 16:A498
21. Van Engen A, Casamayor M, Loftus F, Crimin E, Lacey L (2013) Economic evaluation of fidaxomicin for the treatment of Clostridium difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in Ireland. Value Health 16:A353
22. Debast SB, Bauer MP, Kuijper EJ; European Society of Clinical Microbiology and Infectious Diseases (2014) European Society of Clinical Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect 20(Suppl 2):1–26
23. Eckmann C, Wasserman M, Latif F, Roberts G, Beriot-Mathiot A (2013) Increased hospital length of stay attributable to Clostridium difficile infection in patients with four co-morbidities: an analysis of hospital episode statistics in four European countries. Eur J Health Econ 14(5):835–846
24. Hart WM, Asensio A, Isidoro B, Watt M, Nazir J (2013) The burden of Clostridium difficile in Spain: a retrospective matched-cohort study. PIN 50. ISPOR 16th Annual European Congress. Dublin, pp 2–6
25. Hospital Episode Statistics (HES). Health & Social Care Information Centre (HSCIC). Available online at: http://www.hscic.gov.uk/hes. Accessed 19 Nov 2013
26. Consejo General de Colegios de Farmacéuticos. BOT Plus 2.0. Available online at: https://botplusweb.portalfarma.com/. Accessed 16 Oct 2013
27. Ambulatory Diagnosis-Related Groups of the NHS. General Directorate of Public Health, Quality and Innovation. Specialized outpatient care in the National Health System. Weights and costs of outpatient procedures. IR-GRD 2.3. Ministry of Health, Social Services and Equality, Madrid. September 2013
28. Pubic prices of Extremadura. Order of 7 February, 2014, publishing the updated list of public rates and prices of the Autonomous Community of Extremadura by virtue of the provisions of the General Budgets Law of the Autonomous Community of Extremadura for 2014. DOE no. 34, of 19 February, 2014
29. Public prices of Madrid. Order 731/2013 of 6 September, of the Ministry of Health, setting the public prices for the rendering of health services and activities of the Network of Centres of the Community of Madrid. DOE no. 215, of 30 September, 2013
30. Slobogean GP, O’Brien PJ, Brauer CA (2010) Single-dose versus multiple-dose antibiotic prophylaxis for the surgical treatment of closed fractures. Acta Orthop 81:256–262
31. Henrich TJ, Krakower D, Bitton A, Yokoe DS (2009) Clinical risk factors for severe Clostridium difficile-associated disease. Emerg Infect Dis 15:415–422
32. Karas JA, Enoch DA, Aliyu SH (2010) A review of mortality due to Clostridium difficile infection. J Infect 61:1–8
33. Perras C, Tsakonas E, Ndegwa S, Conly J, Valiquette L, Farrah K (2011) Vancomycin or metronidazole for treatment of Clostridium difficile infection: clinical and economic analyses. Canadian Agency for Drugs and Technologies in Health (CADTH), Ottawa (technology report; no. 136). Available online at: http://www.cadth.ca/media/pdf/H0499_Cdifficile_tr_e.pdf. Accessed 4 Dec 2013
34. The human mortality database. Available online at: http://www.mortality.org/hmd/ESP/STATS/bltper_1x1.txt. Accessed 17 Oct 2013
35. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB (2007) A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45:302–307
36. Greiner W, Weiinen T, Nieuwenhuizen M, Oppe S, Badia X, Busschbach J, Buxton M, Dolan P, Kind P, Krabbe P, Ohinmaa A, Parkin D, Roset M, Sintonen H, Tsuchiya A, de Charro F (2003) A single European currency for EQ-5D health states. Results from a six-country study. Eur J Health Econ 4:222–231
37. Sacristán JA, Oliva J, Del Llano J, Prieto L, Pinto JL (2002) ¿Qué es una tecnología eficiente en España? Gac Sanit 16:334–343
38. Briggs A, Claxton K, Sculpher M (2006) Decision modelling for health economic evaluation. Oxford University Press, Oxford
39. Rubio-Terrés C, Cobo E, Sacristán JA, Prieto L, del Llano J, Badia X; Grupo ECOMED (2004) Análisis de la incertidumbre en las evaluaciones económicas de intervenciones sanitarias. Med Clin (Barc) 122:668–674
40. Dubberke ER, Wertheimer AI (2009) Review of current literature on the economic burden of Clostridium difficile infection. Infect Control Hosp Epidemiol 30:57–66
41. Kuijper EJ, Coignard B, Tüll P; ESCMID Study Group for Clostridium difficile; EU Member States; European Centre for Disease Prevention and Control (2006) Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 12(Suppl 6):2–18
42. Wiegand PN, Nathwani D, Wilcox MH, Stephens J, Shelbaya A, Haider S (2012) Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect 81:1–14
43. Konijeti GG, Sauk J, Shrime MG, Gupta M, Ananthakrishnan AN (2014) Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin Infect Dis 58:1507–1514
44. Di Bella S, Drapeau C, García-Almodóvar E, Petrosillo N (2013) Fecal microbiota transplantation: the state of the art. Infect Dis Rep 5:43–45
45. McCune VL, Struthers JK, Hawkey PM (2014) Faecal transplantation for the treatment of Clostridium difficile infection: a review. Int J Antimicrob Agents 43:201–206
46. Bartsch SM, Umscheid CA, Fishman N, Lee BY (2013) Is fidaxomicin worth the cost? An economic analysis. Clin Infect Dis 57:555–561
47. Rubio Terrés C (2006) Métodos para la realización de evaluaciones económicas de intervenciones sanitarias. GH Contin 5:302–306